OBJECTIVES: To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer's disease (AD). MATERIALS AND METHODS: Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A Quick Test of Cognitive Speed (AQT), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and MMSE were administered concurrently. RESULTS: Correlations (rho) between age and AQT processing speed were non-significant, but were significant for ADAS-Cog and Mini Mental State Examination (MMSE). AQT and ADAS-Cog means did not differ significantly between baseline and endpoint. There was a small, significant reduction in MMSE point scores. Measures of stability (Spearman's rho) were moderate-to-high for all tests. Means for subgroups did not differ as a function of medication type. CONCLUSIONS: AQT processing speed, ADAS-Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.
OBJECTIVES: To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer's disease (AD). MATERIALS AND METHODS: Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A Quick Test of Cognitive Speed (AQT), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and MMSE were administered concurrently. RESULTS: Correlations (rho) between age and AQT processing speed were non-significant, but were significant for ADAS-Cog and Mini Mental State Examination (MMSE). AQT and ADAS-Cog means did not differ significantly between baseline and endpoint. There was a small, significant reduction in MMSE point scores. Measures of stability (Spearman's rho) were moderate-to-high for all tests. Means for subgroups did not differ as a function of medication type. CONCLUSIONS: AQT processing speed, ADAS-Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.
Authors: Clara Vila-Castelar; Jenny J Ly; Lillian Kaplan; Kathleen Van Dyk; Jeffrey T Berger; Lucy O Macina; Jennifer L Stewart; Nancy S Foldi Journal: Arch Clin Neuropsychol Date: 2019-05-01 Impact factor: 2.813
Authors: Sebastian Palmqvist; Lennart Minthon; Carina Wattmo; Elisabet Londos; Oskar Hansson Journal: Alzheimers Res Ther Date: 2010-10-15 Impact factor: 6.982
Authors: Jerker Rönnberg; Thomas Lunner; Elaine Hoi Ning Ng; Björn Lidestam; Adriana Agatha Zekveld; Patrik Sörqvist; Björn Lyxell; Ulf Träff; Wycliffe Yumba; Elisabet Classon; Mathias Hällgren; Birgitta Larsby; Carine Signoret; M Kathleen Pichora-Fuller; Mary Rudner; Henrik Danielsson; Stefan Stenfelt Journal: Int J Audiol Date: 2016-09-02 Impact factor: 2.117
Authors: Niklas Mattsson; Michael Schöll; Olof Strandberg; Ruben Smith; Sebastian Palmqvist; Philip S Insel; Douglas Hägerström; Tomas Ohlsson; Henrik Zetterberg; Jonas Jögi; Kaj Blennow; Oskar Hansson Journal: EMBO Mol Med Date: 2017-09 Impact factor: 12.137
Authors: Niklas Mattsson; Rik Ossenkoppele; Ruben Smith; Olof Strandberg; Tomas Ohlsson; Jonas Jögi; Sebastian Palmqvist; Erik Stomrud; Oskar Hansson Journal: Alzheimers Res Ther Date: 2018-08-07 Impact factor: 6.982